“
“The anatomical correlate of epileptic seizures with ecstatic auras has not been established. We document precise descriptions of the ecstatic seizures experienced by five patients, all of whom reported intense feelings of well-being and a heightened self-awareness. We propose here that the descriptions by these patients, together with the neurophysiological and neuroradiological evidence, support a theoretical framework for understanding ecstatic states based on hyperactivation of the anterior insula, rather than the temporal lobe. Epileptologists who have
access to patients who experience episodic feelings of ecstasy and heightened self-awareness have an opportunity to provide insights that CH5183284 chemical structure might help clarify the neural basis of Consciousness. (C) 2009 Elsevier Inc. All rights reserved.”
“We present an overlooked and noteworthy historical case and illustration of a necrotizing fasciitis, observed SNX-5422 mw and written by John Bell (1763-1820), first
published in 1801. Considering the setting and the clinical presentation, we hypothesize that the pathogen responsible was the species Vibrio vulnificus. The typical clinical course of a rapidly progressive illness preceded by saltwater exposure shortly followed by the development of a hemorrhagic skin lesion, with a fatal outcome, should strongly suggest a V. vulnificus infection. To our knowledge, there are few historical case reports with illustrations included describing cases of necrotizing fasciitis, selleck compound particularly with V. vulnificus as the suggested pathogen. (C) 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.”
“Aim: There is no further treatment option for metastatic colon patients who are refractory to
standard chemotherapy and to whom novel biological agents are not available. We evaluated the outcomes of mitomycin-C, 5-fluorouracil (5-FU) and leucovorin in patients with metastatic colon cancer previously treated with oxaliplatin/5-FU/leucovorin and irinotecan/5-FU/leucovorin.
Methods: We retrospectively analyzed 46 patients who had received mitomycin-C/5FU/leucovorin between March 2008 and December 2009. All patients had failed prior first-line and second-line therapy containing oxaliplatin, irinotecan, and 5-FU.
Results: The median age of the patients was 57.0 years (range, 34.0-76.0) and their median Eastern Cooperative Oncology Group performance status was 1 (0-2). A complete or partial response was not observed in any patient and stable disease was observed in 19 patients (41.3%). The median duration of follow up was 29 weeks (range 8-87 weeks). Median progression-free survival was 10 weeks (95% CI 8-12) and median overall survival was 38 weeks (95% CI 32-44). Grade 3 and 4 hematological toxicities included neutropenia in five patients (10.8%) and thrombocytopenia in four patients (8.8%). Grade 3 or 4 non-hematologic toxicities included nausea and vomiting in two patients. There were no treatment-related deaths.